$3.23
+0.63 (+24.23%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where XTLB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 0 tracked-famous managers · FINRA short interest 7.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral NeuropathyNCT00597649Pain and safetyRandomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: The 001 trial did not show benefit versus placebo | Drug: Bicifadine | Chronic Peripheral Neuropathy Pain in Diabetics | 250 | Dec 2008actual | 2009-06-30 |
| Study of XTL6865 in Patients With Chronic Hepatitis C Virus InfectionNCT00300807log change in serum concentrations of HCV RNARandomized · Double-masked · Treatment | Phase 1 | Unknown status | Drug: XTL 6865 | Hepatitis C | 36 | — | 2007-03-07 |
| Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With DiabetesNCT00553592Pain and SafetyRandomized · Triple-masked · Treatment | Phase 2 | Unknown status | Drug: Bicifadine, Bicifadine, Bicifadine | Diabetic Peripheral Neuropathy | 336 | — | 2007-11-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19